Cancer and Systemic Lupus Erythematosus

Abstract

Link to publication on Research at Birmingham portal General rightsUnless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.• Users may freely distribute the URL that is used to identify this publication.• Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.• User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?) • Users may not further distribute the material nor use it for the purposes of commercial gain.Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.When citing, please reference the published version. Take down policyWhile the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

Systematic Construction and Validation of a Novel Macrophage Differentiation–Associated Prognostic Model for Clear Cell Renal Cell Carcinoma

“…A previous study showed that systemic lupus erythematosus is highly associated with increased cancer risk compared with the general population ( Song et al, 2018 ). The underlying pathophysiologic mechanisms are still not fully understood, but possible factors include lupus-related medications, inherent immune system abnormalities, viral infections, and/or traditional cancer risk factors ( Ladouceur et al, 2020 ). Other pathways which significantly enriched in a high-risk cohort include the RIG l (retinoic acid inducible-gene 1)-like receptor signaling pathway, the NOD (nucleotide-binding oligomerization domain)-like receptor signaling pathway, the cytoplasmic DNA sensing pathway, antigen processing and presentation, primary immunodeficiency, etc.…”

Vital Hepatic Lymphoma Residuum or Excessive Immune Response? Challenging Treatment Decisions in a Patient With Systemic Lupus Erythematosus and Liver-Dominant Diffuse Large B-Cell Lymphoma: Case Report

“…As SLE increases the risk of NHL by fourfold ( 2 ), it seems tempting to speculate that the DLBCL arose secondary to the chronic inflammatory disease. Indeed, the presented case suggests a possible link between autoimmune reactive diseases as an underlying chronic inflammatory trigger factor for NHL, a phenomenon that is particularly known in extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue lymphomas ( 13 ).…”

“…Diffused large B-cell lymphoma (DLBCL) is a highly heterogeneous disease and represents the most common subtype of non-Hodgkin’s lymphoma (NHL) in adult patients ( 1 ). Systemic lupus erythematosus (SLE) increases the risk of NHL by fourfold mainly attributed to the chronic inflammatory state, dysregulation of cytokines, and higher expression of a proliferation-inducing ligand ( 2 ). The main connecting feature of both diseases is that the B cells are at the center of the respective pathophysiological changes.…”

Cancer and rheumatic diseases. Methodological and clinical pitfalls in searching links between these diseases

“…While SLE is associated with a 4-fold increased risk of non-Hodgkin lymphoma, some studies report a decreased risk of female hormone-dependent cancers: breast, ovarian and endometrial [20][21][22]. Several studies also reported increased risk of cervical, vulva/vaginal, head and neck, thyroid, bladder and kidney, liver and nonmelanoma skin cancer in patients with SLE [20,21,[23][24][25][26][27]. The risk of malignancy in scleroderma has been described in three meta-analyses [28][29][30][31].…”